Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 206Colonic Neoplasms 89Rectal Neoplasms 88Stomach Neoplasms 57Pancreatic Neoplasms 49Neoplasms 42Esophageal Neoplasms 42Neoplasm Metastasis 39Unspecified Adult Solid Tumor, Protocol Specific 30Lung Neoplasms 28Glioblastoma 27Brain Neoplasms 26Carcinoma, Non-Small-Cell Lung 24Central Nervous System Neoplasms 23Glioma 22Small Cell Lung Carcinoma 21Neuroblastoma 20Astrocytoma 18Adenocarcinoma Of Esophagus 18Esophageal Squamous Cell Carcinoma 17Gliosarcoma 16Breast Neoplasms 15Rhabdomyosarcoma 13Oligodendroglioma 12Sarcoma 11Adenocarcinoma 10Medulloblastoma 9Carcinoma, Hepatocellular 9Sarcoma, Ewing 8Gastrointestinal Neoplasms 8

Interventions

trifluridine tipiracil drug combination 1tipiracil 1Trifluridine 1Taxes 1Irinotecan 1Gastrectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gastric Adenocarcinoma × Irinotecan × Clear all
NCT04074343 2024-02-02

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

University of California, Irvine

Phase 1 Completed
20 enrolled 9 charts
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡